- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05559853
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
December 18, 2023 updated by: Memorial Sloan Kettering Cancer Center
Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
94
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ouri Cohen, PhD
- Phone Number: 646-608-8259
- Email: coheno1@mskcc.org
Study Contact Backup
- Name: Nelson Moss, MD
- Phone Number: 212-639-7075
- Email: mossn@mskcc.org
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contact:
- Ouri Coheb, PhD
- Phone Number: 646-608-8259
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The study investigators will discuss participant potentially eligible for research participation within their interdisciplinary brain metastasis disease management team.
These potential participants will then be contacted by their treating physician or investigator team.
Study investigators will prioritize consenting participants who are planned to undergo SRS and, when possible, will attempt to coordinate the research scan with their clinically necessary MRI scans to minimize time and disruption for the participant.
Description
Inclusion Criteria:
Healthy volunteers [for Study Aim 1 (SA1)] will be entered into the study if they meet the following criteria:
- Age ≥ 18 years
- Able to understand and give informed consent
- No known cancer diagnosis
Patients [for Study Aim 3 (SA3)] will be entered into the study if they meet the following criteria:
- Age ≥ 18 years
- Able to understand and give informed consent
- At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
- Planned SRS treatment
Exclusion Criteria:
Healthy volunteers (SA1) and patients (SA2) exclusion criteria:
- Pregnant or breastfeeding women
- Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
- Age < 18 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with Brain Metastases
Participants will have at least one untreated brain metastasis > 1cm
|
CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
Other Names:
|
Healthy participants
Participants will have no known cancer diagnosis
|
CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion
Time Frame: Up to 3 years
|
Develop a rapid and robust 3D CEST-MRF pulse sequence for clinical scanners using our preclinical CEST-MRF pulse sequence as a basis by evaluating the changes of the 6 CEST-MRF parameters with and without motion.
These parameters include the water T1 and T2 relaxation (T1w,T2w), amide exchange rate (ksw) and volume fraction (fs) and the semi-solid exchange rate (kssw) and volume fraction (fss).
|
Up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ouri Cohen, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2022
Primary Completion (Estimated)
September 22, 2027
Study Completion (Estimated)
September 22, 2027
Study Registration Dates
First Submitted
September 22, 2022
First Submitted That Met QC Criteria
September 27, 2022
First Posted (Actual)
September 29, 2022
Study Record Updates
Last Update Posted (Estimated)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 18, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-191
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials.
The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov
when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required.
Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication.
Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals.
Requests may be made to: crdatashare@mskcc.org.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
University of Vermont Medical CenterRecruiting
-
University Hospital, BrestRecruiting
-
Ohio State University Comprehensive Cancer CenterRecruitingBrain Metastases, AdultUnited States
-
Allegheny Singer Research Institute (also known...Elekta LimitedRecruitingBrain Metastases, AdultUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteTerminatedMultiple Brain MetastasesUnited States
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...CompletedBrain Cancer | Neoplasm MetastasesChina
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomUnknown
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
Clinical Trials on CEST-MRF
-
Case Comprehensive Cancer CenterRecruiting
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonUnknown
-
King's College Hospital NHS TrustKing's College LondonRecruitingStroke, AcuteUnited Kingdom
-
Massachusetts General HospitalCompletedSmall Cell Lung Carcinoma | Non-small Cell Lung CarcinomaUnited States
-
Case Comprehensive Cancer CenterThe Cleveland ClinicNot yet recruitingBrain Tumor | Brain Metastases | Brain NecrosisUnited States
-
Case Comprehensive Cancer CenterTerminatedGlioma | Brain Tumor | Neurofibromatosis Type 1United States
-
University of Nevada, RenoCompletedDepression, AnxietyUnited States
-
Institut de cancérologie Strasbourg EuropeRecruitingGlioma | Brain MetastasesFrance
-
University of ArizonaTerminatedBreast CancerUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingBrain Metastases | Pulmonary Cancer | RadionecrosisFrance